ASH 2022 | FLT3 mutational status can change between diagnosis and relapse in patients with AML

Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines findings from a study which identified patients with acute myeloid leukemia (AML) who relapsed with emergent FLT3 mutation (FLT3m) and compared their clinical and pathological characteristics to those who relapsed without FLT3m. Overall, it was found that FLT3m can occur at the time of relapse even in patients who had a FLT3-wild type disease. Acquisition of new genetic mutations and clonal evolution was also observed at time of relapse in patients. The majority of patients in the study maintained a FLT3m between diagnosis and relapse, and these patients were found to have worse overall survival (OS) compared to other groups. With the study demonstrating that FLT3 mutational status can change between diagnosis and relapse, Dr Haddad emphasizes that it is crucial to check for FLT3m at relapse, irrespective of what the mutational status was at diagnosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.